- Home
- GILD vs PBR Comparison
GILD vs PBR Comparison
Compare GILD & PBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GILD | PBR |
|---|---|---|
| Founded | 1987 | 1953 |
| Country | United States | Brazil |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 187.4B | 165.6B |
| IPO Year | 2003 | 2016 |
Fundamental Metrics
Financial Performance| Metric | GILD | PBR |
|---|---|---|
| Price | $156.45 | $26.19 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 28 | 14 |
| Target Price | ★ $159.85 | $24.09 |
| AVG Volume (30 Days) | 4.9M | ★ 21.8M |
| Earning Date | 10-29-2026 | 11-10-2026 |
| Dividend Yield | 2.09% | ★ 4.63% |
| EPS Growth | ★ 1684.21 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $24,689,000,000.00 | N/A |
| Revenue This Year | $4.36 | $21.75 |
| Revenue Next Year | $6.88 | N/A |
| P/E Ratio | ★ N/A | $13.55 |
| Revenue Growth | ★ 9.98 | N/A |
| 52 Week Low | $114.02 | $11.43 |
| 52 Week High | $160.51 | $26.12 |
Technical Indicators
Market Signals| Indicator | GILD | PBR |
|---|---|---|
| Relative Strength Index (RSI) | 60.52 | 73.14 |
| Support Level | $142.91 | $19.22 |
| Resistance Level | $158.90 | N/A |
| Average True Range (ATR) | 3.75 | 0.68 |
| MACD | 0.55 | 0.01 |
| Stochastic Oscillator | 81.19 | 93.55 |
Price Performance
Historical ComparisonAbout GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About PBR Petroleo Brasileiro S.A.- Petrobras
Petrobras is a Brazil-based integrated energy company controlled by the Brazilian government. The company focuses on the exploration and production of oil and gas in Brazilian offshore fields. Production in 2025 was 3.0 million barrels of oil equivalent per day (80% oil), and reserves stood at 12.1 billion boe (84% oil). At the end of 2025, Petrobras operated 10 refineries in Brazil with a capacity of 1.8 million barrels per day and distributed refined products and natural gas throughout the country.